文献速递头颈部肿瘤放疗放疗物理与技术

EORTC 1219-DAHANCA-29 试验中 HPV/p16 阴性头颈鳞癌放疗质量保证:基准病例流程结果

Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
PubMed 文献 · Radiother Oncol · 2017-05-04

该研究在 III 期 EORTC 1219-DAHANCA 29 试验患者入组前开展两步基准病例(BC)流程,包括勾画与计划练习,并由中心前瞻性审核反馈。重提交后 DSI 升高、HD 降低,计划练习未发现不可接受变异。结论强调临床试验中有效前瞻性放疗质量保证(RTQA)的必要性,勾画而非计划是不可接受方案变异的主要原因。

要点

  • 勾画步骤中 47% 中心需重复 2 次、16% 需重复 3 次才获批准。
  • 重提交后 DSI 升高、HD 降低,尤其预防性临床靶区(pCTV);计划练习无不可接受变异。

核心结论

  • 基准病例结果强调临床试验中需要有效且前瞻性的放疗质量保证(RTQA)。
  • 即使方案指南明确,勾画而非计划仍是不可接受方案变异的主要原因。
  • 未来试验引入 HD 和 DSI 等更客观的定量分析方法可能加强专家评估。

研究设计与样本

  • 参与中心按方案指南完成两步基准病例:勾画和计划练习。
  • 提交材料接受前瞻性中心审核并向提交中心反馈。
  • 回顾性使用 Sørensen-Dice 相似指数(DSI)和第 95 百分位 Hausdorff 距离(HD)评估中心与专家勾画的一致性。

主要发现

  • 9 个(47%)中心需进行勾画步骤两次、3 个(16%)中心需三次才获得批准。
  • 重提交病例中 DSI 值升高、HD 降低,尤其预防性临床靶区(pCTV)。
  • 计划练习未发现不可接受变异。

关键数值与推荐

  • 勾画步骤中 9 个(47%)中心需重复 2 次、3 个(16%)中心需重复 3 次才获批准。
  • 重提交病例中 DSI 值升高、HD 降低,尤其针对预防性临床靶区(pCTV)。
  • 计划练习未发现不可接受变异。

临床怎么用

  • 在头颈癌放疗临床试验中实施前瞻性放疗质量保证(RTQA)和基准病例流程。
  • 对勾画环节重点审核,因勾画而非计划是不可接受方案变异的主要来源。
  • 可考虑引入 HD 和 DSI 等定量指标辅助专家评估勾画一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The phase III EORTC 1219-DAHANCA 29 intergroup trial evaluates the influence of nimorazole in patients with locally advanced head and neck cancer when treated with accelerated radiotherapy (RT) in combination with chemotherapy. This article describes the results of the RT Benchmark Case (BC) performed before patient inclusion. MATERIALS AND METHODS: The participating centers were asked to perform a 2-step BC, consisting of (1) a delineation and (2) a planning exercise according to the protocol guidelines. Submissions were prospectively centrally reviewed and feedback was given to the submitting centers. Sørensen-Dice similarity index (DSI) and the 95th percentile Hausdorff distance (HD) were retrospectively used to evaluate the agreement between the centers and the expert contours. RESULTS: Fifty-four submissions (34 delineation and 20 planning exercises) from 19 centers were reviewed. Nine (47%) centers needed to perform the delineation step twice and three (16%) centers 3 times before receiving an approval. An increase in DSI-value and a decrease in HD, in particular for the prophylactic Clinical Target Volume (pCTV), could be found for the resubmitted cases. No unacceptable variations could be found for the planning exercise. CONCLUSIONS: These BC-results highlight the need for effective and prospective RTQA in clinical trials. Even with clearly defined protocol guidelines, delineation and not planning remain the main reason for unacceptable protocol variations. The introduction of more objective quantitative analysis methods, such as the HD and DSI, in future trials might strengthen the evaluation by experts.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Christiaens M, Collette S, Overgaard J, et al. Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiother Oncol. 2017. PMID: 28478912. doi:10.1016/j.radonc.2017.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。